Browsing by Author "Rojo, Federico"

Sort by: Order: Results:

  • Vincent, Theresa; Neve, Etienne P.A.; Johnson, Jill R.; Kukalev, Alexander; Rojo, Federico; Albanell Mestres, Joan; Pietras, Kristian; Virtanen, Ismo; Philipson, Lennart; Leopold, Philip L.; Crystal, Ronald G.; García de Herreros, Antonio; Moustakas, Aristidis; Petterson, Ralf F.; Fuxe, Jonas (Nature Research, 2009)
    Epithelial-mesenchymal transition (EMT) is essential for organogenesis and is triggered during carcinoma progression to an invasive state. Transforming growth factor-beta (TGF-beta) cooperates with signalling pathways, ...
  • Colomer, Ramon; Aranda-Lopez, Ignacio; Albanell Mestres, Joan; García-Caballero, Tomás; Ciruelos, Eva; Lopez-García, M. A.; Cortés, J.; Rojo, Federico; Martín, M.; Palacios-Calvo, J. (SpringerOpen, 2018)
    This consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society of Medical Oncology and the Spanish ...
  • Dalmases Massegú, Alba, 1982-; González González, Irene; Menendez Romero, Silvia; Arpí Llucià, Oriol; Corominas Torres, Josep Maria; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Chamizo, Cristina; Rincón, Raúl; Espinosa Blay, Lluís; Bigas Salvans, Anna; Eroles, Pilar; Furriol, Jessica; Lluch, Ana; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico (Impact Journals, 2014)
    NF-кB has been linked to doxorubicin resistance in breast cancer patients. NF-кB nuclear translocation and DNA binding in doxorubicin treated-breast cancer cells have been extensively examined; however its functional ...
  • Pavlovic, Milica, 1985-; Arnal-Estapé, Anna ; Rojo, Federico; Bellmunt, Anna ; Tarragona, Maria ; Guiu, Marc; Planet, Evarist; Garcia-Albéniz, Xabier; Morales, Mònica; Urosevic, Jelena ; Gawrzak, Sylwia ; Rovira Guerín, Ana; Prat, Aleix; Nonell Mazelón, Lara; Lluch, Ana; Jean-Mairet, Joël ; Coleman, Robert ; Albanell Mestres, Joan; Gomis, Roger R. (Oxford Open , 2015)
    BACKGROUND: There are currently no biomarkers for early breast cancer patient populations at risk of bone metastasis. Identification of mediators of bone metastasis could be of clinical interest. METHODS: A de novo unbiased ...
  • Carracedo, Alma; Egervari, Kristof; Salido, Marta; Rojo, Federico; Arumí, Montserrat; Corominas Torres, Josep Maria; Corzo, Cristina; Tusquets Trias de Bes, Ignacio; Espinet Solà, Blanca; Rovira Guerín, Ana; Albanell Mestres, Joan; Szollosi, Zoltan; Serrano Figueras, Sergi; Solé Ristol, Francesc (BioMed Central, 2009)
  • Slebe Concha, Juan Felipe, 1981-; Rojo, Federico; Vinaixa, Maria; García-Rocha, Mar; Testoni, Giorgia; Guiu, Marc; Planet, Evarist; Samino, Sara; Arenas, Enrique J.; Beltran, Antoni; Rovira Guerín, Ana; Lluch, Ana; Salvatella, Xavier; Yanes, Oscar; Albanell Mestres, Joan; Guinovart, Joan J. (Joan Josep), 1947-; Gomis, Roger R. (Nature Publishing Group, 2016)
    The mechanisms that allow breast cancer (BCa) cells to metabolically sustain rapid growth are poorly understood. Here we report that BCa cells are dependent on a mechanism to supply precursors for intracellular lipid ...
  • Zazo, Sandra; González-Alonso, Paula; Martín-Aparicio, Ester; Chamizo, Cristina; Cristóbal, Ion; Arpí Llucià, Oriol; Rovira Guerín, Ana; Albanell Mestres, Joan; Eroles, Pilar; Lluch, Ana; Madoz-Gúrpide, Juan; Rojo, Federico (e-Century Publishing, 2017)
    Trastuzumab became the therapy of choice for patients with HER2-positive breast cancer in 1998, and it has provided clinical benefit ever since. However, a significant percentage of patients show primary resistance to ...
  • Bellmunt Molins, Joaquim, 1959-; Werner, Lillian; Bamias, Aristotle; Fay, André P.; Park, Rachel S.; Riester, Markus; Selvarajah, Shamini; Barletta, Justine A.; Berman, David M.; Muga, Silvia de; Salido, Marta; Gallardo, Enrique; Rojo, Federico; Guancial, Elizabeth A.; Bambury, Richard; Mullane, Stephanie A.; Choueiri, Toni K.; Loda, Massimo; Stack, Edward; Rosenberg, Jonathan (Wiley, 2015)
    We evaluated primary tumors from two cohorts, Spain (N = 111) and Greece (N = 102), for patients who were treated with platinum-based chemotherapy. Patients were tested for HER2 status (IHC score of 3+ or FISH ratio of ...
  • Berghoff, Anna S.; Bellosillo Paricio, Beatriz; Caux, Christophe; de Langen, Adrianus; Mazieres, Julien; Normanno, Nicola; Preusser, Matthias; Provencio, Mariano; Rojo, Federico; Wolf, Jurgen; Zielinski, Christoph C. (BMJ Publishing Group, 2019)
    The introduction of targeted treatments and more recently immune checkpoint inhibitors (ICI) to the treatment of metastatic non-small cell lung cancer (NSCLC) has dramatically changed the prognosis of selected patients. ...
  • Inglés Esteve, Julia; Morales, Mònica; Dalmases Massegú, Alba, 1982-; Garcia Carbonell, Ricard; Jené i Sanz, Alba, 1984-; López Bigas, Núria; Iglesias Coma, Mar; Ruiz Herguido, Cristina; Rovira Guerín, Ana; Rojo, Federico; Albanell Mestres, Joan; Gomis, Roger R.; Bigas Salvans, Anna; Espinosa Blay, Lluís (Public Library of Science (PLoS), 2012)
    14-3-3σ is frequently lost in human breast cancers by genetic deletion or promoter methylation. We have now investigated the involvement of 14-3-3σ in the termination of NF-κB signal in mammary cells and its putative role ...
  • Muntasell i Castellví, Aura, 1972-; Cabo, Mariona; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Martínez-García, Maria; Rovira Guerín, Ana; Rojo, Federico; Albanell Mestres, Joan; López-Botet, Miguel (Frontiers, 2017)
    Overexpression of the human epidermal growth factor receptor 2 (HER2) defines a subgroup of breast tumors with aggressive behavior. The addition of HER2-targeted antibodies (i.e., trastuzumab, pertuzumab) to chemotherapy ...
  • Remon, Jordi; García-Campelo, R.; Álava, Enrique de; Vera, R.; Rodríguez Peraltó, José Luís; Rodríguez-Lescure, Á.; Bellosillo Paricio, Beatriz; Garrido, P.; Rojo, Federico; Álvarez-Alegret, R. (Springer, 2020)
    The proportion of cancer patients with tumours that harbour a potentially targetable genomic alteration is growing considerably. The diagnosis of these genomic alterations can lead to tailored treatment at the onset of ...
  • Prieto-Potin, Iván; Montagut Viladot, Clara; Bellosillo Paricio, Beatriz; Rojo, Federico (Elsevier, 2018)
    Treatment of colorectal cancer (CRC) with monoclonal antibodies against epidermal growth factor receptor requires the assessment of the mutational status of exons 2, 3, and 4 of the NRAS and KRAS oncogenes. Moreover, the ...
  • Hernández Prat, Anna, 1984-; Rodriguez-Vida, Alejo; Juanpere, Nuria; Arpí Llucià, Oriol; Menéndez, Silvia; Soria-Jiménez, Luis; Martínez, Alejandro; Iarchouk, Natalia; Rojo, Federico; Albanell Mestres, Joan; Brake, Rachael; Rovira Guerín, Ana; Bellmunt Molins, Joaquim, 1959- (American Association for Cancer Research (AACR), 2019)
    Advanced bladder cancer is associated with a poor prognosis and limited treatment options. The PI3K/AKT/mTOR pathway is frequently activated in this disease and can be a potential therapeutic target for treatment intervention. ...
  • Mateu Jiménez, Mercè; Fermoselle Pérez, Clara, 1985-; Rojo, Federico; Mateu de Antonio, Francisco Javier; Peña, Raúl; Urtreger, Alejandro J.; Diament, Miriam J.; Joffé, Elisa D. Bal de Kier; Pijuan Andujar, Lara; García de Herreros, Antonio; Barreiro Portela, Esther (Bentham Science Publishers, 2016)
    Lung cancer (LC) remains the leading cause of cancer mortality worldwide, and non-small cell LC (NSCLC) represents 80% of all LC. Oxidative stress and inflammation, autophagy, ubiquitin-proteasome system, nuclear factor ...
  • Rincón, Raúl; Cristóbal, Ion; Zazo, Sandra; Arpí Llucià, Oriol; Menendez Romero, Silvia; Manso, Rebeca; Lluch, Ana; Eroles, Pilar; Rovira Guerín, Ana; Albanell Mestres, Joan; García-Foncillas, Jesús; Madoz-Gúrpide, Juan; Rojo, Federico (Impact Journals, 2015)
    The protein phosphatase 2A (PP2A) is a key tumor suppressor which has emerged as a novel molecular target in some human cancers. Here, we show that PP2A inhibition is a common event in breast cancer and identified PP2A ...
  • García-Foncillas, Jesús; Tabernero Cartula, Josep; Élez, Elena; Aranda, Enrique; Benavides, Manuel; Camps, Carlos; Jantus-Lewintre, Eloisa; López, Rafael; Muinelo-Romay, Laura; Montagut Viladot, Clara; Antón, Antonio; López, Guillermo; Díaz-Rubio, Eduardo; Rojo, Federico; Vivancos Prellezo, Ana (Nature Research, 2018)
    BACKGROUND: Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation ...
  • González-Alonso, Paula; Arpí Llucià, Oriol; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico (MDPI, 2020)
    Trastuzumab is the first-line targeted therapeutic drug for HER2-positive breast cancer, leading to improved overall survival. However, acquired resistance inevitably occurs. We aimed to identify, quantify, and assess the ...
  • Tormo, Eduardo; Ballester, Sandra; Adam-Artigues, Anna; Burgués, Octavio; Alonso, Elisa; Bermejo, Begoña; Menendez Romero, Silvia; Zazo, Sandra; Madoz-Gúrpide, Juan; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico; Lluch, Ana; Eroles, Pilar (Nature Research, 2019)
    The mechanisms of chemotherapy resistance in triple negative breast cancer remain unclear, and so, new molecules which might mediate this resistance could optimize treatment response. Here we analyzed the involvement of ...
  • Tormo, Eduardo; Adam-Artigues, Anna; Ballester, Sandra; Pineda, Begoña; Zazo, Sandra; González-Alonso, Paula; Albanell Mestres, Joan; Rovira Guerín, Ana; Rojo, Federico; Lluch, Ana; Eroles, Pilar (Nature Publishing Group, 2017)
    A subset of HER2+ breast cancer patients manifest clinical resistance to trastuzumab. Recently, miR-26a and miR-30b have been identified as trastuzumab response regulators, and their target gene CCNE2 seems to play an ...